Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Vitrafy Life Sciences Ltd. ( (AU:VFY) ) has shared an announcement.
Vitrafy Life Sciences Limited has updated the remuneration arrangements for its Managing Director and CEO, Brent Owens. The changes include the removal of the Short-Term Incentive and an increase in the Long-Term Incentive from 60% to 100% of Fixed Annual Remuneration, aligning the CEO’s remuneration with shareholder interests and emphasizing sustainable long-term performance.
The most recent analyst rating on (AU:VFY) stock is a Buy with a A$2.30 price target. To see the full list of analyst forecasts on Vitrafy Life Sciences Ltd. stock, see the AU:VFY Stock Forecast page.
More about Vitrafy Life Sciences Ltd.
Vitrafy Life Sciences Limited is an Australian company specializing in cryopreservation solutions. It offers a proprietary range of smart cryopreservation hardware and Lifechain™, a cloud-based software platform, to ensure the preservation of biomaterial quality. The company is headquartered in Melbourne, Australia, with a manufacturing facility and laboratory in Ballarat, Victoria, and is listed on the Australian Securities Exchange (ASX: VFY).
Average Trading Volume: 15,035
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$86.2M
Find detailed analytics on VFY stock on TipRanks’ Stock Analysis page.